Sean Robbins has more than 20 years of experience in pricing and reimbursement in the pharmaceutical industry.

He has launched several products globally; and developed pricing and market access strategies for pharmaceutical products across the lifecycle. Most recently, he has developed strategies; and has been the primary lead for execution for the reimbursement for more than 15 ODD products in EU. He has been a thought leader in developing strategies and tactics to combat International Reference Pricing; and providing advice to companies about what they can do to better prepare for reference pricing.

He is the author of several publications in clinical and health economics journals; and has been involved in the development of pricing defence strategies for several of the early biosimilars launched in Europe. He was one of the only early advocates in pharma to institute value-based selling programs with “the field”; bringing Pricing Function and Key Account Management teams closer together to fostering shared goals in pricing execution. Sean is currently an Adjunct Professor at the University of Southern California in the Titus School of Pharmacy and Health Policy where he teaches pharmaceutical pricing and reimbursement. Sean is passionate about introducing profit enhancing pricing analytics and novel market access strategies into pharmaceutical companies to help drive improvements in company’s bottom line.

Ted joined LatticePoint in July 2016 and provides advisory services to early-stage companies in the cell and gene therapy space and has advised on market access, EMA Adaptive Pathways, international expansion, talent acquisition, and key customer relationships.

Prior to consulting, he spent 17 years working in the pharmaceutical industry and headed the Market Access function for Genzyme’s Rare Disease Business Unit and Pfizer’s Head of Head of Market Access, Primary Care BU. Before joining Pfizer, he spent 7 years at Schering-Plough in various regional and affiliate finance roles.

Ted began his career at Deloitte & Touche, including two years in Frankfurt, Germany and is a qualified SEC Audit Committee Financial Expert.

He is a frequent speaker on gene therapy pricing and has published on reforming payment for cell and gene therapies with colleagues from the Alliance for Regenerative Medicine.

He has a BS degree in accounting from Villanova University, a Master of Arts in International Affairs from The Fletcher School of Law & Diplomacy at Tufts University, and an MBA from the Leonard N. Stern School of Business at New York University. He speaks fluent German in addition to his native English.

Jordi joined LatticePoint in  2024. He holds a PhD in Biomedicine from the Universitat Autonoma de Barcelona, Spain and an executive MBA from ESADE law and business school.

He has been involved in +30 strategy and M&A projects. He has specialized in biotech and pharma companies, as well as CDMOs. He has worked for public and private companies, listed in EU and US, as well as Fortune500 companies and biotech unicorns. He has worked in different drug modalities, being very active in nuclear medicine and advanced therapy space.

He has more than 10 years of experience in scientific research, with a bachelor in biotechnology and a master in neuroscience. He obtained his PhD in 2016 at the CRG. After his postdoctoral experience, Jordi started working as an entrepreneur in residence, he is an inventor and co-founder of a biotech developing novel RNA modifying compounds for the treatment of oncological malignancies.

In addition to his scientific and entrepreneurship experience, Jordi holds an executive MBA from ESADE, law and business school.

Jordi has been awarded several grants and prices, like La Caixa International PhD Fellowship program and CERCA Pioneer Price for his thesis, Caixa Impulse 2017, European Research Council Proof of Concept 2017, Industria del Coneixement Producte 2018, Worldwide Cancer Research UK, Caixa Impulse Consolidate 2021, and EIC Transition.

Ela joined LatticePoint in  2020. She holds a PhD in Biomedicine from the University of Barcelona, Spain.

Ela joined LatticePoint with the aim of using her scientific skill set to help tackle issues closer to patient’s bedside. At LatticePoint she translated her excitement about the multidimensional nature of market access field into support of market access strategy projects for different European healthcare systems. Ela performs primary and secondary research, develops value communication tools, and contributes to writing of reimbursement dossiers and scientific publications as well as development of health economic models. During her time at LatticePoint, she built knowledge in disease areas like oncology, infectious diseases, and autoimmune disorders, and explored the world of advanced medicine therapies. Ela appreciates strategy-oriented discussions and an environment that promotes growth.

Before transitioning into consulting, Ela was a scientist in molecular biophysics field. She obtained a PhD from the University of Barcelona in Spain. In her research she focused on a question – what can we understand about intrinsically disordered proteins to change their label from undruggable to druggable? Investigation of the question led to several publications leaving her ready for new challenges.

Benjamin has practical experience developing cost-effectiveness models in Excel or R. He also designed modeling, analysis, and data visualization tools targeting internal and external audiences.

Additionally, Benjamin has hands-on experience with value-based pricing, evidence gap analysis, and pipeline prioritization for multi-indication assets. He also contributed to writing European reimbursement dossiers. He participated in projects that evaluated the impact of new regulations, such as the new EU Pharma strategy and IRA, on access and pricing of oncology products.

Before joining LatticePoint, Benjamin worked as an associate scientist at Debiopharm International. He was a project leader at Transcure bioServices, overseeing in vivo immune-oncology studies for international pharmaceutical clients.

At LatticePoint, Efe is responsible for market access in Turkey, developing tailored pricing and reimbursement strategies, and providing life-cycle support for medicinal products. He is also responsible for the retained payer panel database with a large collection of key stakeholders ranging from payers, prescribers, HTA advisors to medical key opinion leaders in US, Europe and parts of Asia.

Efe supports the development of payer value propositions, reimbursement dossiers, and evidence generation plans for innovative medicines entering the European market. Particularly, he has experience in writing reimbursement dossiers in the Netherlands. He also works on identifying sources of high-quality epidemiological, clinical, and real-world data.

Before moving into the consulting sector, Efe was specialized in cell-based therapies against malignant cancers. Efe developed and optimized T cell receptor affinity-engineered CD8 T cells targeting melanoma. Due to his scientific background, he is particularly interested in cell-based therapies, immune-checkpoint inhibitors, and other oncology medicines.

Johannes joined LatticePoint in 2023. He obtained an M.Sc. in physics from the RWTH Aachen University (Germany) and a PhD for work in medical physics at the European Organization for Nuclear Research (CERN), Switzerland, and RWTH Aachen University.

Johannes has more than 6 years of experience in R&D of medical devices, gained during his PhD and post-doc work. His research was based at CERN and focused on detector development for radiation therapy of cancer patients.

In addition, Johannes has 1.5 years of experience in a consulting company for regulatory affairs for medical devices, where he established regulatory pathways (mainly for the EU and the USA), defined clinical strategies, and performed and reviewed clinical evaluations for medical devices in the EU following MDR and MDD legislations.

In LatticePoint, Benedetta has been involved in several value-based indication evaluation and prioritization projects, assessing products’ values from scientific, clinical, and market potential perspectives. Understanding the indications and the competitive landscape, her goal is to support the development of clinical strategies and evidence-generation plans, ensuring the capture of the real unmet needs and evidence gaps.

She has experience in pricing and reimbursement strategies for different European countries, with specific expertise in market access in Italy. She is responsible for the payer panel database, with a large collection of key stakeholders ranging from payers, prescribers, and HTA advisors to medical key opinion leaders in the US, Europe, and parts of Asia.

Prior to consulting, Benedetta specialized in the field of medicinal chemistry. In particular, her projects were focused on the development of potential future drug candidates for the treatment of inflammatory diseases and antibiotic resistance.

Estelle joined LatticePoint in 2022. She holds an M.Sc. in Human Biology from the University of Zurich (Switzerland), and she performed a Cifre Ph.D. in Cellular and molecular biology at the University of Caen-Normandie (France) in collaboration with Op2Lysis.

Estelle has a research background in Neurovascular diseases and thrombolysis. She worked on developing a new thrombolytic agent to be used in stroke. Before joining LatticePoint, Estelle worked as an MSL for HRA Pharma and as a research associate for Op2Lysis, where she oversaw the development of research protocol and preclinical development.

Agnes joined LatticePoint in 2023. Her educational foundation was laid at the Technical University of Munich in Germany, where she completed both her bachelor’s and master’s degrees in biochemistry. Her academic carrier continued at Utrecht University in the Netherlands, where she pursued her PhD.

Her research primarily revolved around the study of large biomolecular systems, with a special emphasis on the dynamic interactions of microtubules with microtubule-associated proteins. For example, Agnes studied the Tau protein which is associated with neurodegeneration and the MAP7 protein overexpressed in several cancers.